Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
 |
New Vision (Kampala) - December 2, 2007
But if the newborn got infected, they were more likely to acquire a strain of HIV that was resistant to drugs raising the question of whether it was worth the risk.
A partial solution to this dilemma may be at hand, according to a study in The Lancet.
In a trial, 199 of 397 HIV+pregnant women at two health centres in Lusaka, Zambia, were given single doses of two other drugs - tenofovir and emtricitabine - along with the niverapine during birth.
The other 198 were given niverapine only. Both groups also took a small dose of a fourth drug, zidovudine.
Results showed the absolute risk of getting HIV was cut in half: 12% percent for the test group and 25% for the control group.
These results show adding tenofovir/emtricitabine to standard treatments may reduce maternal nevirapine resistance.
071202
NV071201
Copyright © 2007 - The New Vision. All articles are republished on AEGIS by permission. Material may not be redistributed, posted to any other location, published or used for broadcast without written authorization from Managing Director/Editor-in-chief, The New Vision, P.O. Box 9815, Kampala - Uganda, Tel/fax: 256-41-235221, E-mail: wpike@newvision.co.ug.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .